文献速递白血病

Guadecitabine与治疗选择在新诊断急性髓系白血病中的全球3期随机研究

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
PubMed 文献 · Blood Adv · 2023-01-01

这项3期研究评估了新型低甲基化药物guadecitabine(n=408)与预选治疗选择(TC;n=407,包括阿扎胞苷、地西他滨或低剂量阿糖胞苷)在不适合接受强化诱导化疗的急性髓系白血病患者中的疗效和安全性。50%的患者东部肿瘤协作组体能状态评分为2-3分。共同主要终点完全缓解率在guadecitabine组和TC组分别为19%和17%(分层P=0.48),中位总生存期分别为7.1个月和8.5个月(HR 0.97;95%CI 0.83-1.14;分层log-rank P=0.73)。结论认为在总体人群中guadecitabine与TC的疗效无显著差异。

要点

  • 在总体人群中,guadecitabine与TC的完全缓解率和总生存期均无显著差异。
  • 事后分析中,接受≥4个治疗周期的患者,guadecitabine组中位生存期长于TC组(15.6 vs 13.0个月;HR 0.78;95%CI 0.64-0.96;log-rank P=0.02)。
  • 两组≥3级不良事件发生率无显著差异(guadecitabine 92% vs TC 88%),但guadecitabine组≥3级发热性中性粒细胞减少、中性粒细胞减少和肺炎发生率更高。

核心结论

  • 在总体人群中,未观察到guadecitabine与TC的疗效存在显著差异。

研究设计与样本

  • 全球3期随机研究,纳入不适合接受强化诱导化疗的新诊断急性髓系白血病患者,guadecitabine组n=408,TC组n=407。
  • TC为预选治疗选择,包括阿扎胞苷、地西他滨或低剂量阿糖胞苷。
  • 共同主要终点为完全缓解和总生存期。
  • 试验注册号为NCT02348489。

主要发现

  • 完全缓解率:guadecitabine组19% vs TC组17%(分层P=0.48)。
  • 中位总生存期:guadecitabine组7.1个月 vs TC组8.5个月(HR 0.97;95%CI 0.83-1.14;分层log-rank P=0.73)。
  • 1年生存率:guadecitabine组37% vs TC组36%;2年生存率:guadecitabine组18% vs TC组14%。
  • 两组中较大比例患者(42%)接受<4个治疗周期。
  • 事后分析中,接受≥4个治疗周期的患者,guadecitabine组中位生存期15.6个月 vs TC组13.0个月(HR 0.78;95%CI 0.64-0.96;log-rank P=0.02)。

关键数值与推荐

  • 完全缓解率:guadecitabine组19% vs TC组17%(分层P=0.48)。
  • 中位总生存期:guadecitabine组7.1个月 vs TC组8.5个月(HR 0.97;95%CI 0.83-1.14;分层log-rank P=0.73)。
  • 接受≥4个治疗周期的患者事后分析:guadecitabine组中位生存期15.6个月 vs TC组13.0个月(HR 0.78;95%CI 0.64-0.96;log-rank P=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 3 study evaluated the efficacy and safety of the new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n = 407) of azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia unfit to receive intensive induction chemotherapy. Half of the patients (50%) had poor Eastern Cooperative Oncology Group Performance Status (2-3). The coprimary end points were complete remission (19% and 17% of patients for guadecitabine and TC, respectively [stratified P = .48]) and overall survival (median survival 7.1 and 8.5 months for guadecitabine and TC, respectively [hazard ratio, 0.97; 95% confidence interval, 0.83-1.14; stratified log-rank P = .73]). One- and 2-year survival estimates were 37% and 18% for guadecitabine and 36% and 14% for TC, respectively. A large proportion of patients (42%) received <4 cycles of treatment in both the arms. In a post hoc analysis of patients who received ≥4 treatment cycles, guadecitabine was associated with longer median survival vs TC (15.6 vs 13.0 months [hazard ratio, 0.78; 95% confidence interval, 0.64-0.96; log-rank P = .02]). There was no significant difference in the proportion of patients with grade ≥3 adverse events (AEs) between guadecitabine (92%) and TC (88%); however, grade ≥3 AEs of febrile neutropenia, neutropenia, and pneumonia were higher with guadecitabine. In conclusion, no significant difference was observed in the efficacy of guadecitabine and TC in the overall population. This trial was registered at www.clinicaltrials.gov as #NCT02348489.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fenaux P, Gobbi M, Kropf PL, et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023. PMID: 37276510. doi:10.1182/bloodadvances.2023010179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。